JP6505016B2 - 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 - Google Patents
強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 Download PDFInfo
- Publication number
- JP6505016B2 JP6505016B2 JP2015538330A JP2015538330A JP6505016B2 JP 6505016 B2 JP6505016 B2 JP 6505016B2 JP 2015538330 A JP2015538330 A JP 2015538330A JP 2015538330 A JP2015538330 A JP 2015538330A JP 6505016 B2 JP6505016 B2 JP 6505016B2
- Authority
- JP
- Japan
- Prior art keywords
- mva
- promoter
- virus
- seq
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title description 25
- 230000005875 antibody response Effects 0.000 title description 13
- 239000002773 nucleotide Substances 0.000 claims description 76
- 125000003729 nucleotide group Chemical group 0.000 claims description 76
- 239000000427 antigen Substances 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 72
- 108091007433 antigens Proteins 0.000 claims description 72
- 241000700605 Viruses Species 0.000 claims description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
- 230000005867 T cell response Effects 0.000 claims description 35
- 150000007523 nucleic acids Chemical group 0.000 claims description 34
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 17
- 208000007089 vaccinia Diseases 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 42
- 230000003053 immunization Effects 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 238000002649 immunization Methods 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 29
- 241000124008 Mammalia Species 0.000 description 26
- 238000000034 method Methods 0.000 description 22
- 229960005486 vaccine Drugs 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 20
- 239000013598 vector Substances 0.000 description 20
- 108700026244 Open Reading Frames Proteins 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 16
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 14
- 101100272150 Vaccinia virus (strain Copenhagen) B8R gene Proteins 0.000 description 13
- 101100272151 Vaccinia virus (strain Western Reserve) VACWR190 gene Proteins 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 241000700647 Variola virus Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 8
- 230000001172 regenerating effect Effects 0.000 description 8
- 241000700663 Avipoxvirus Species 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102000043129 MHC class I family Human genes 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108700009124 Transcription Initiation Site Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 230000004543 DNA replication Effects 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 230000017613 viral reproduction Effects 0.000 description 4
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 3
- 241000178270 Canarypox virus Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700629 Orthopoxvirus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 101100451260 Arabidopsis thaliana HMGS gene Proteins 0.000 description 2
- 101150020569 B3R gene Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150046614 C15L gene Proteins 0.000 description 2
- 241001137864 Camelpox virus Species 0.000 description 2
- 241000700664 Capripoxvirus Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000700639 Parapoxvirus Species 0.000 description 2
- 241001569977 Penguinpox virus Species 0.000 description 2
- 241000700667 Pigeonpox virus Species 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 241000569181 Quailpox virus Species 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101100280283 Vaccinia virus (strain Copenhagen) F11L gene Proteins 0.000 description 2
- 101100540425 Vaccinia virus (strain Copenhagen) VGF gene Proteins 0.000 description 2
- 101100280285 Vaccinia virus (strain Western Reserve) VACWR050 gene Proteins 0.000 description 2
- 241000726423 Variola major virus Species 0.000 description 2
- 241000700574 Yatapoxvirus Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 208000008813 mosaic variegated aneuploidy syndrome Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 102220059024 rs747802641 Human genes 0.000 description 2
- 229940083538 smallpox vaccine Drugs 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 1
- 101150011225 5L gene Proteins 0.000 description 1
- 101150068622 ATI gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000700628 Chordopoxvirinae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000725630 Ectromelia virus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 description 1
- 241000928771 Horsepox virus Species 0.000 description 1
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000700559 Molluscipoxvirus Species 0.000 description 1
- 241001028048 Nicola Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 241001455645 Rabbitpox virus Species 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000385708 Turkeypox virus Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010046861 Vaccination complication Diseases 0.000 description 1
- 101100054108 Vaccinia virus (strain Copenhagen) A44L gene Proteins 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002235 anthrax antigen Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- -1 antioxidants Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000007203 infectious ectromelia Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719429P | 2012-10-28 | 2012-10-28 | |
| US61/719,429 | 2012-10-28 | ||
| PCT/EP2013/003239 WO2014063832A1 (en) | 2012-10-28 | 2013-10-28 | Pr13.5 promoter for robust t-cell and antibody responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019054129A Division JP6818797B2 (ja) | 2012-10-28 | 2019-03-22 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533841A JP2015533841A (ja) | 2015-11-26 |
| JP2015533841A5 JP2015533841A5 (enExample) | 2016-10-20 |
| JP6505016B2 true JP6505016B2 (ja) | 2019-04-24 |
Family
ID=49513897
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538330A Active JP6505016B2 (ja) | 2012-10-28 | 2013-10-28 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
| JP2019054129A Active JP6818797B2 (ja) | 2012-10-28 | 2019-03-22 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019054129A Active JP6818797B2 (ja) | 2012-10-28 | 2019-03-22 | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9828414B2 (enExample) |
| EP (2) | EP2912183B1 (enExample) |
| JP (2) | JP6505016B2 (enExample) |
| KR (2) | KR20200087880A (enExample) |
| CN (1) | CN104755622B (enExample) |
| AU (1) | AU2013337018B2 (enExample) |
| BR (1) | BR112015009320A2 (enExample) |
| CA (1) | CA2887623C (enExample) |
| CY (1) | CY1123181T1 (enExample) |
| DK (1) | DK2912183T3 (enExample) |
| EA (2) | EA032498B1 (enExample) |
| ES (1) | ES2800623T3 (enExample) |
| HK (1) | HK1212383A1 (enExample) |
| HU (1) | HUE049706T2 (enExample) |
| IL (1) | IL238130B (enExample) |
| IN (1) | IN2015DN03326A (enExample) |
| LT (1) | LT2912183T (enExample) |
| MX (2) | MX380483B (enExample) |
| MY (2) | MY194609A (enExample) |
| NZ (1) | NZ706637A (enExample) |
| PT (1) | PT2912183T (enExample) |
| SG (2) | SG11201503200PA (enExample) |
| SI (1) | SI2912183T1 (enExample) |
| UA (1) | UA118340C2 (enExample) |
| WO (1) | WO2014063832A1 (enExample) |
| ZA (1) | ZA201502892B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2887623C (en) * | 2012-10-28 | 2021-02-16 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| PL3407910T3 (pl) | 2016-01-29 | 2022-08-16 | Bavarian Nordic A/S | Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni |
| CA3021341A1 (en) * | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| NZ752275A (en) | 2016-09-28 | 2025-07-25 | Bavarian Nordic As | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| DK3562946T3 (da) | 2016-12-28 | 2022-01-31 | Transgene Sa | Oncolytiske virusser og terapeutiske molekyler |
| KR20200015759A (ko) | 2017-06-15 | 2020-02-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| IL272546B2 (en) | 2017-08-24 | 2024-01-01 | Bavarian Nordic As | Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody |
| SG11202005710YA (en) | 2017-12-19 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
| GB201807932D0 (en) | 2018-05-16 | 2018-06-27 | Redchenko Irina | Compositions and methods for inducing an immune response |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CN110904127B (zh) | 2018-09-18 | 2024-09-20 | 瓦赫宁恩研究基金会 | 非洲猪瘟病毒疫苗 |
| CA3113818A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| SG11202104918PA (en) | 2018-11-20 | 2021-06-29 | Bavarian Nordic As | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| IL293009B1 (en) | 2019-11-20 | 2025-09-01 | Bavarian Nordic As | Recombinant mva viruses for intratumoral and/or intravenous administration for cancer treatment |
| KR20230022206A (ko) | 2020-06-10 | 2023-02-14 | 버베리안 노딕 에이/에스 | 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신 |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| WO2023031428A1 (en) | 2021-09-03 | 2023-03-09 | Bavarian Nordic A/S | Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva) |
| WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| AU2023298083A1 (en) | 2022-06-29 | 2025-01-09 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
| JP2025528219A (ja) | 2022-08-18 | 2025-08-26 | トランジェーヌ | キメラポックスウイルス |
| IL321887A (en) | 2023-01-12 | 2025-09-01 | Bavarian Nordic As | Recombinantly modified Sarna (vrp) for cancer vaccine |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2025238218A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding antigen-displaying protein nanoparticles |
| WO2025238219A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles |
| WO2025238220A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles |
| WO2025238221A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding multi-antigen-displaying protein nanoparticles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| PL1773387T3 (pl) * | 2004-06-25 | 2013-10-31 | Merial Inc | Rekombinanty wirusa ospy ptasiej wyrażające geny wirusa pryszczycy |
| JP2008301792A (ja) | 2007-06-11 | 2008-12-18 | National Univ Corp Shizuoka Univ | 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法 |
| DK2367944T3 (en) | 2008-11-27 | 2019-04-15 | Bavarian Nordic As | PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| CA2887623C (en) * | 2012-10-28 | 2021-02-16 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
-
2013
- 2013-10-28 CA CA2887623A patent/CA2887623C/en active Active
- 2013-10-28 CN CN201380054013.0A patent/CN104755622B/zh active Active
- 2013-10-28 PT PT137838520T patent/PT2912183T/pt unknown
- 2013-10-28 JP JP2015538330A patent/JP6505016B2/ja active Active
- 2013-10-28 AU AU2013337018A patent/AU2013337018B2/en active Active
- 2013-10-28 IN IN3326DEN2015 patent/IN2015DN03326A/en unknown
- 2013-10-28 KR KR1020207020263A patent/KR20200087880A/ko not_active Ceased
- 2013-10-28 MX MX2015005264A patent/MX380483B/es unknown
- 2013-10-28 EP EP13783852.0A patent/EP2912183B1/en active Active
- 2013-10-28 WO PCT/EP2013/003239 patent/WO2014063832A1/en not_active Ceased
- 2013-10-28 UA UAA201505223A patent/UA118340C2/uk unknown
- 2013-10-28 SI SI201331731T patent/SI2912183T1/sl unknown
- 2013-10-28 HK HK16100267.8A patent/HK1212383A1/xx unknown
- 2013-10-28 MY MYPI2018001787A patent/MY194609A/en unknown
- 2013-10-28 MY MYPI2015701223A patent/MY171687A/en unknown
- 2013-10-28 DK DK13783852.0T patent/DK2912183T3/da active
- 2013-10-28 LT LTEP13783852.0T patent/LT2912183T/lt unknown
- 2013-10-28 HU HUE13783852A patent/HUE049706T2/hu unknown
- 2013-10-28 ES ES13783852T patent/ES2800623T3/es active Active
- 2013-10-28 EA EA201590831A patent/EA032498B1/ru not_active IP Right Cessation
- 2013-10-28 SG SG11201503200PA patent/SG11201503200PA/en unknown
- 2013-10-28 SG SG10201704657WA patent/SG10201704657WA/en unknown
- 2013-10-28 EA EA201990114A patent/EA201990114A1/ru unknown
- 2013-10-28 KR KR1020157009206A patent/KR102135818B1/ko active Active
- 2013-10-28 EP EP20172647.8A patent/EP3778904A1/en active Pending
- 2013-10-28 BR BR112015009320A patent/BR112015009320A2/pt not_active Application Discontinuation
- 2013-10-28 US US14/437,939 patent/US9828414B2/en active Active
- 2013-10-28 NZ NZ706637A patent/NZ706637A/en unknown
-
2015
- 2015-04-02 IL IL238130A patent/IL238130B/en active IP Right Grant
- 2015-04-24 MX MX2021001638A patent/MX2021001638A/es unknown
- 2015-04-28 ZA ZA2015/02892A patent/ZA201502892B/en unknown
-
2017
- 2017-11-22 US US15/821,035 patent/US11028130B2/en active Active
-
2019
- 2019-03-22 JP JP2019054129A patent/JP6818797B2/ja active Active
-
2020
- 2020-07-08 CY CY20201100630T patent/CY1123181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6818797B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| CN102341120B (zh) | 结合重复免疫的优化早晚期启动子辅助对复制缺陷型重组病毒疫苗抗原的细胞毒t细胞应答 | |
| US10111946B2 (en) | Poxviral vectors for low antibody response after a first priming immunization | |
| US9163237B2 (en) | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements | |
| AU2017228587B2 (en) | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines | |
| HK40044708A (en) | Pr13.5 promoter for robust t-cell and antibody responses | |
| EA045254B1 (ru) | Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций | |
| HK1161677B (en) | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160902 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170913 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181127 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190306 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190326 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6505016 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |